He Took It to Mexico. Now It’s Back in the U.S. A Phase 2 clinical trial has begun enrolling patients in the United States for an experimental immunotherapy designed to treat metastatic prostate cancer, according to its developer, Syncromune, Inc. The trial would test an idea both simple and unsettling: freeze part of the…